Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2024
0mins
Should l Buy FHTX?
Source: Newsfilter
Foghorn Therapeutics Conference Participation: Foghorn Therapeutics Inc. will participate in multiple healthcare conferences, including the Jefferies London Healthcare Conference, Evercore HealthCONx Conference, and Citi Global Healthcare Conference, with CEO Adrian Gottschalk presenting at fireside chats and engaging in one-on-one meetings.
Innovative Gene Therapy Approach: The company is focused on developing a new class of medicines using its Gene Traffic Control® platform to target genetically determined dependencies within the chromatin regulatory system, primarily aimed at oncology treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FHTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FHTX
Wall Street analysts forecast FHTX stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.260
Low
9.00
Averages
11.38
High
14.00
Current: 5.260
Low
9.00
Averages
11.38
High
14.00
About FHTX
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Foghorn Therapeutics to Participate in Biotech Summit
- Summit Participation: Foghorn Therapeutics will participate in the Guggenheim Emerging Outlook Biotech Summit on February 11-12, 2026, in New York, showcasing its innovative drug development in oncology.
- Management Presentation: CEO Adrian Gottschalk is scheduled to present on February 11 at 3:00 PM EST, sharing the latest advancements in the company's gene expression correction efforts, which is expected to attract investor interest.
- Webcast Availability: The presentation will be webcasted under the 'Events & Presentations' section of the company's website and will be available for replay for 30 days, enhancing investor engagement.
- R&D Platform: Foghorn's Gene Traffic Control® platform focuses on developing drug candidates targeting genetically determined dependencies, aiming to drive therapeutic innovation in oncology with significant market potential.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
See More
Foghorn Therapeutics Raises $50 Million to Advance Cancer Treatments
- Successful Financing: Foghorn Therapeutics secured $50 million in equity financing with investors including BVF Partners, expected to close on January 13, 2026, at a price of $6.71 per share, representing a 30% premium to the January 9 closing price, providing robust funding for future R&D initiatives.
- Strong Financial Position: Post-financing, the company anticipates cash and cash equivalents to reach approximately $208.9 million, ensuring continued investment in its pipeline over the next two years, particularly for the FHD-909 project targeting SMARCA4-mutant cancers.
- Clinical Trial Progress: The Phase 1 dose-escalation trial of FHD-909 is advancing as planned, primarily targeting patients with non-small cell lung cancer, which is expected to offer new treatment options in this high-need area and improve patient prognosis.
- Drug Development Outlook: Foghorn's selective CBP and EP300 degrader programs are on track to be IND-ready in 2026, demonstrating potential applications in ER+ breast cancer and hematologic malignancies, further solidifying the company's innovative position in oncology treatment.
See More
Foghorn Therapeutics Raises $50 Million to Advance Cancer Treatments
- Successful Financing: Foghorn Therapeutics has secured $50 million in equity financing with investors including BVF Partners, expected to close on January 13, 2026, at a 30% premium, reflecting strong investor confidence in the company's strategic vision.
- Strong Financial Position: Post-financing, the company anticipates having approximately $208.9 million in cash and equivalents, ensuring continued investment in its pipeline and extending its cash runway into the first half of 2028, thereby enhancing its viability in the competitive biotech landscape.
- Clinical Trial Progress: The Phase 1 dose-escalation trial of FHD-909 is advancing as planned, targeting patients with SMARCA4-mutant non-small cell lung cancer, which is expected to provide new treatment options and address significant unmet medical needs in this area.
- Drug Development Outlook: Foghorn's selective CBP and EP300 degrader programs are on track to be IND-ready in 2026, showcasing the company's innovative potential in oncology and the possibility of transforming existing treatment paradigms.
See More
Foghorn Therapeutics to Participate in Biotech Summit
- Summit Participation: Foghorn Therapeutics will participate in the Guggenheim Emerging Outlook Biotech Summit on February 11-12, 2026, in New York, showcasing its innovative drug development in oncology.
- Management Presentation: CEO Adrian Gottschalk is scheduled to present on February 11 at 3:00 PM EST, sharing the latest advancements in the company's gene expression correction efforts, which is expected to attract investor interest.
- Webcast Availability: The presentation will be webcasted under the 'Events & Presentations' section of the company's website and will be available for replay for 30 days, enhancing investor engagement.
- R&D Platform: Foghorn's Gene Traffic Control® platform focuses on developing drug candidates targeting genetically determined dependencies, aiming to drive therapeutic innovation in oncology with significant market potential.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
See More
Foghorn Therapeutics Raises $50 Million to Advance Cancer Treatments
- Successful Financing: Foghorn Therapeutics secured $50 million in equity financing with investors including BVF Partners, expected to close on January 13, 2026, at a price of $6.71 per share, representing a 30% premium to the January 9 closing price, providing robust funding for future R&D initiatives.
- Strong Financial Position: Post-financing, the company anticipates cash and cash equivalents to reach approximately $208.9 million, ensuring continued investment in its pipeline over the next two years, particularly for the FHD-909 project targeting SMARCA4-mutant cancers.
- Clinical Trial Progress: The Phase 1 dose-escalation trial of FHD-909 is advancing as planned, primarily targeting patients with non-small cell lung cancer, which is expected to offer new treatment options in this high-need area and improve patient prognosis.
- Drug Development Outlook: Foghorn's selective CBP and EP300 degrader programs are on track to be IND-ready in 2026, demonstrating potential applications in ER+ breast cancer and hematologic malignancies, further solidifying the company's innovative position in oncology treatment.
See More
Foghorn Therapeutics Raises $50 Million to Advance Cancer Treatments
- Successful Financing: Foghorn Therapeutics has secured $50 million in equity financing with investors including BVF Partners, expected to close on January 13, 2026, at a 30% premium, reflecting strong investor confidence in the company's strategic vision.
- Strong Financial Position: Post-financing, the company anticipates having approximately $208.9 million in cash and equivalents, ensuring continued investment in its pipeline and extending its cash runway into the first half of 2028, thereby enhancing its viability in the competitive biotech landscape.
- Clinical Trial Progress: The Phase 1 dose-escalation trial of FHD-909 is advancing as planned, targeting patients with SMARCA4-mutant non-small cell lung cancer, which is expected to provide new treatment options and address significant unmet medical needs in this area.
- Drug Development Outlook: Foghorn's selective CBP and EP300 degrader programs are on track to be IND-ready in 2026, showcasing the company's innovative potential in oncology and the possibility of transforming existing treatment paradigms.
See More
